ClinicalTrials.gg
CompletedNCT05931380ATTAIN-JUpdated Jul 20, 2026Results posted

A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

A Phase 3 interventional study of Orforglipron and Placebo in Obesity, sponsored by Eli Lilly and Company. Completed at 16 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
238
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.

Enrollment
13th of 22
238 · median 324
Started
2023
with 5 others
Phase 3
14 of 22
3 open now
Registered
7th of 22
by date
Lead sponsor
21 of 22
Eli Lilly and Company

Among the 22 studies testing orforglipron in Obesity, this one is the 13th largest by enrollment, is one of 6 that started in 2023, is one of 14 in phase 3, and was the 7th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing orforglipron in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.

03

Conditions studied

  • Obesity

Keywords

  • Overweight
  • Metabolism and Nutrition Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a ≥27 kg/m² and \<35 kg/m² and at least 2 obesity-related health problems (treated or untreated), OR a BMI ≥35 kg/m² and at least 1 obesity-related health problem (treated or untreated). At least one obesity-related health problem should be hypertension, dyslipidemia or T2D (approximately 25% of participants).
  • Have a history of at least one self-reported unsuccessful dietary effort to lose body weight.
  • Males and females may participate in this trial. Female participants must not be pregnant, intending to be pregnant, breastfeeding, or intending to breastfeed.
  • use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • No male contraception is required except in compliance with specific local government study requirements.

Exclusion criteria

Exclusion Criteria:

  • For participants with Type 2 Diabetes (T2D):

    • Have Type 1 Diabetes (T1D), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2D.
    • Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within the 180 days prior to screening.
  • Have renal impairment measured as estimated (eGFR) \<15 mL/min/1.73 m², calculated by Japanese Society of Nephrology coefficient-modified chronic kidney disease-epidemiology equation during screening.
  • Have a known gastric emptying abnormality.
  • For participants without Type 2 diabetes (T2D): Have any type of diabetes with (HbA1c) ≥6.5 %.
  • Have a self-reported change in body weight >5 kg (11 pounds) within 90 days prior to screening.
  • Have chronic kidney disease.
  • Have lupus or rheumatoid arthritis.
  • Have the following cardiovascular conditions within 90 days prior to screening.
  • Have acute or chronic hepatitis.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
238 participants (actual)

Study arms

  • Placebo comparator
    Placebo QD

    Participants received matching placebo capsule orally once daily (QD). Treatment was initiated with placebo corresponding to 1 mg equivalent to Orforglipron, with dose escalation every 4 weeks to maintain blinding, and was continued through Week 72, unless dose interruption or modification was required. Treatment was administered as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: Placebo

  • Experimental
    6 mg Orforglipron QD

    Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 6 mg, which was maintained through Week 72, unless dose interruption or modification was required. Treatment was administered as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: Orforglipron

  • Experimental
    12 mg Orforglipron QD

    Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 12 mg, which was maintained through Week 72, unless dose interruption or modification was required. Treatment was administered as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: Orforglipron

  • Experimental
    36 mg Orforglipron QD

    Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 36 mg, which was maintained through Week 72, unless dose interruption or modification was required. Treatment was administered as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: Orforglipron

Interventions

  • Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight at Week 72

    Values reported as "LS Mean" are model-based estimates (MBE) of the adjusted (unconditional) treatment effect. MBEs was calculated using an analysis of covariance (ANCOVA) model with the following variables: treatment group, baseline value, baseline Body Mass Index (BMI) category (\<35 kilogram per meter square \[kg/m²\] or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).

    Time frame: Baseline, Week 72

  2. Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline

    Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.

    Time frame: Baseline to Week 72

Secondary outcomes

  1. Percentage of Participants Who Achieved ≥10% Body Weight Reduction From Baseline

    Percentage of participants with ≥10% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.

    Time frame: Baseline to Week 72

  2. Percentage of Participants Who Achieved ≥15% Body Weight Reduction From Baseline

    Percentage of participants with ≥15% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.

    Time frame: Baseline to Week 72

  3. Percentage of Participants Who Achieved ≥20% Body Weight Reduction From Baseline

    Percentage of participants with ≥20% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.

    Time frame: Baseline to Week 72

  4. Change From Baseline in Body Mass Index (BMI) at Week 72

    Values reported as "LS Mean" are model-based estimates (MBE) of the adjusted (unconditional) treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.

    Time frame: Baseline, Week 72

  5. Percentage of Participants Who Had Improvements in Hypertension

    Percentage of participants achieving hypertension improvement ((Systolic blood pressure \<130 mmHg and diastolic blood pressure \<80 mmHg) was analysed using logistic regression with the following variables: treatment, baseline BMI group, and strata in the model. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). The estimates (odds ratio and corresponding confidence intervals) were derived using observed data.

    Time frame: Baseline to Week 72

  6. Percentage of Participants Who Had Improvements in Dyslipidemia

    Percentage of participants achieving dyslipidemia improvement (Low-density lipoprotein cholesterol \<140 milligrams per deciliter (mg/dL), triglycerides \<150 mg/dL, and high-density lipoprotein cholesterol ≥40 mg/dL) was analysed using logistic regression with the following variables: treatment, baseline BMI group, and strata in the model. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). The estimates (odds ratio and corresponding confidence intervals) were derived using observed data.

    Time frame: Baseline to Week 72

  7. Percentage of Participants Who Achieve Hemoglobin A1c (HbA1c) Target Value (<6.5% [48 mmol/Mol])

    Percentage of participants achieving HbA1c \<6.5% was analysed using logistic regression with the following variables: baseline, treatment, baseline BMI group, and sex in the model, including treatment-by-baseline and treatment-by-sex interaction terms.

    Time frame: Baseline to Week 72

  8. Mean Change From Baseline in Visceral Adipose Tissue (VAT) at Week 72

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).

    Time frame: Baseline, Week 72

  9. Mean Change From Baseline in Waist Circumference at Umbilical Level at Week 72

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).

    Time frame: Baseline, Week 72

  10. Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 72

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).

    Time frame: Baseline, Week 72

  11. Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) at Week 72

    Values represented as LS means are model-based estimates (MBE) of the unconditional average treatment effect on the log-transformed scale. MBE was calculated using an ANCOVA model for log(Actual Value/Baseline), including log-transformed baseline, treatment, baseline BMI group, and strata (defined by joint levels of sex \[female, male\] and baseline type 2 diabetes status \[yes, no\]) as covariates, with treatment-by-log(baseline) and treatment-by-strata interaction terms included in the model.

    Time frame: Baseline, Week 72

  12. Percent Change From Baseline in High Density Lipoprotein (HDL) at Week 72

    Values represented as LS means are model-based estimates (MBE) of the unconditional average treatment effect on the log-transformed scale. MBE was calculated using an ANCOVA model for log(Actual Value/Baseline), including log-transformed baseline, treatment, baseline BMI group, and strata (defined by joint levels of sex \[female, male\] and baseline type 2 diabetes status \[yes, no\]) as covariates, with treatment-by-log(baseline) and treatment-by-strata interaction terms included in the model.

    Time frame: Baseline, Week 72

  13. Percent Change From Baseline in Triglycerides at Week 72

    Values represented as LS means are model-based estimates (MBE) of the unconditional average treatment effect on the log-transformed scale. MBE was calculated using an ANCOVA model for log(Actual Value/Baseline), including log-transformed baseline, treatment, baseline BMI group, and strata (defined by joint levels of sex \[female, male\] and baseline type 2 diabetes status \[yes, no\]) as covariates, with treatment-by-log(baseline) and treatment-by-strata interaction terms included in the model.

    Time frame: Baseline, Week 72

  14. Mean Change From Baseline in Fasting Glucose at Week 72

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).

    Time frame: Baseline, Week 72

  15. Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 72

    * Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. * Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).

    Time frame: Baseline, Week 72

  16. Mean Change From Baseline in High-sensitivity C-reactive Protein at Week 72

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed model for repeated measures (MMRM) with the following variables: baseline BMI group, baseline-by-time-by-treatment, and strata-by-time-by-treatment interaction terms in the model. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). An unstructured variance-covariance matrix was used.

    Time frame: Baseline, Week 72

  17. Time to Onset of Type 2 Diabetes (T2D)

    Time to event was defined as the duration from randomization to adjudication committee-confirmed diagnosis of type 2 diabetes mellitus (T2D). Descriptive statistics are presented as Kaplan-Meier estimates of time to onset of T2D (in weeks). Time to onset of T2D was also analyzed using a Cox proportional hazards model, with treatment (pooled orforglipron dose groups) and sex as factors and baseline fasting serum glucose as a covariate. Hazard ratios with corresponding confidence intervals were estimated and reported in statistical analysis. Statistical significance between treatment groups was assessed using a two-sided log-rank test.

    Time frame: Up to Week 72

  18. Mean Change From Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form For Domain and Component Scores at Week 72

    The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Each domain is scored individually and information from these 8 domains is further aggregated into 2 health component summary scores, a Physical Component Summary, and a Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T scores, with mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.

    Time frame: Baseline, Week 72

  19. Mean Change From Baseline in Impact of Weight on Quality-of-Life Lite Clinical Trials Version (IWQOL-Lite-CT) of Physical Function, Physical, and Psychosocial Composite Score at Week 72

    The IWQOL-Lite-CT is a 20-item, obesity-specific patient reported outcome instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life: physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. The two domain scores (Physical and Psychosocial) and composite score (Physical function) range from 0 to 100 with higher scores indicating greater functioning. Raw scores are then linearly transformed to a 0 (worst) -100 (best) scale using: 100×(average item score-1)/4. Higher scores indicate better quality of life/function; lower scores indicate greater impairment.

    Time frame: Baseline, Week 72

  20. Pharmacokinetics (PK): Mean Plasma Concentration of Orforglipron

    Plasma concentrations of orforglipron were measured at predefined pre-dose and post-dose sampling time points.

    Time frame: Pre-dose at Weeks 8, 24, and 48; post-dose at Week 16 (4 to 12 hours) and Week 36 (1 to 4 hours)

07

Results

Posted Jul 20, 2026

Participant flow

Participant flow — Overall Study
MilestonePlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Started60615760
Received at least one dose of study drug60615760
Completed54545254
Not completed6756
Withdrew: Adverse event0122
Withdrew: Death0001
Withdrew: Lost to follow-up2001
Withdrew: Physician decision1000
Withdrew: Protocol deviation1120
Withdrew: Withdrawal by subject2512

Outcome measures

PrimaryPercent Change From Baseline in Body Weight at Week 72

Values reported as "LS Mean" are model-based estimates (MBE) of the adjusted (unconditional) treatment effect. MBEs was calculated using an analysis of covariance (ANCOVA) model with the following variables: treatment group, baseline value, baseline Body Mass Index (BMI) category (\<35 kilogram per meter square \[kg/m²\] or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight at Week 72
percent changePlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percent Change From Baseline in Body Weight at Week 72-0.63 ± 0.732-5.90 ± 0.866-8.69 ± 1.136-7.93 ± 1.063
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -5.28 · 95% CI -7.52 to -3.03
  • Placebo QD vs 12 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -8.06 · 95% CI -10.72 to -5.39
  • Placebo QD vs 36 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -7.30 · 95% CI -9.81 to -4.78
PrimaryPercentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline

Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.

Time frame:
Baseline to Week 72
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline
Percentage of ParticipantsPlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline15.0045.9061.4058.33
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 30.36 · 95% CI 15.09 to 45.62
  • Placebo QD vs 12 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 45.54 · 95% CI 29.64 to 61.44
  • Placebo QD vs 36 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 43.53 · 95% CI 27.71 to 59.35
SecondaryPercentage of Participants Who Achieved ≥10% Body Weight Reduction From Baseline

Percentage of participants with ≥10% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.

Time frame:
Baseline to Week 72
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved ≥10% Body Weight Reduction From Baseline
Percentage of ParticipantsPlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants Who Achieved ≥10% Body Weight Reduction From Baseline3.3318.0335.0938.33
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · Regression, Logistic · p = 0.004 · Risk difference (rd): 15.80 · 95% CI 5.04 to 26.57
  • Placebo QD vs 12 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 32.39 · 95% CI 18.99 to 45.79
  • Placebo QD vs 36 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 36.42 · 95% CI 23.27 to 49.56
SecondaryPercentage of Participants Who Achieved ≥15% Body Weight Reduction From Baseline

Percentage of participants with ≥15% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.

Time frame:
Baseline to Week 72
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved ≥15% Body Weight Reduction From Baseline
Percentage of ParticipantsPlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants Who Achieved ≥15% Body Weight Reduction From Baseline09.8422.8118.33
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · Regression, Logistic · p = 0.012 · Risk difference (rd): 10.04 · 95% CI 2.26 to 17.82
  • Placebo QD vs 12 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 22.38 · 95% CI 11.41 to 33.35
  • Placebo QD vs 36 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 17.54 · 95% CI 8.06 to 27.02
SecondaryPercentage of Participants Who Achieved ≥20% Body Weight Reduction From Baseline

Percentage of participants with ≥20% body weight reduction was analysed by Logistic regression with the following variables: treatment group, baseline value, baseline BMI category (\<35 kg/m² or ≥35 kg/m²), and stratification factors (sex and baseline type 2 diabetes status). Stratification factors were defined by the combination of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.

Time frame:
Baseline to Week 72
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved ≥20% Body Weight Reduction From Baseline
Percentage of ParticipantsPlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants Who Achieved ≥20% Body Weight Reduction From Baseline03.2812.288.33
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · Regression, Logistic · p = 0.136 · Risk difference (rd): 3.62 · 95% CI -1.15 to 8.40
  • Placebo QD vs 12 mg Orforglipron QD · Regression, Logistic · p = 0.007 · Risk difference (rd): 11.74 · 95% CI 3.27 to 20.21
  • Placebo QD vs 36 mg Orforglipron QD · Regression, Logistic · p = 0.028 · Risk difference (rd): 7.82 · 95% CI 0.86 to 14.78
SecondaryChange From Baseline in Body Mass Index (BMI) at Week 72

Values reported as "LS Mean" are model-based estimates (MBE) of the adjusted (unconditional) treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). The model also allowed the treatment effect to vary across baseline values and stratification factors.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · kilograms per meter square (kg/m^2)
Change From Baseline in Body Mass Index (BMI) at Week 72
kilograms per meter square (kg/m^2)Placebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Change From Baseline in Body Mass Index (BMI) at Week 72-0.21 ± 0.230-1.94 ± 0.271-2.83 ± 0.354-2.63 ± 0.355
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -1.73 · 95% CI -2.43 to -1.02
  • Placebo QD vs 12 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -2.62 · 95% CI -3.45 to -1.78
  • Placebo QD vs 36 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -2.41 · 95% CI -3.25 to -1.58
SecondaryPercentage of Participants Who Had Improvements in Hypertension

Percentage of participants achieving hypertension improvement ((Systolic blood pressure \<130 mmHg and diastolic blood pressure \<80 mmHg) was analysed using logistic regression with the following variables: treatment, baseline BMI group, and strata in the model. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). The estimates (odds ratio and corresponding confidence intervals) were derived using observed data.

Time frame:
Baseline to Week 72
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had Improvements in Hypertension
Percentage of ParticipantsPlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants Who Had Improvements in Hypertension14.934.730.023.5
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · Regression, Logistic · p = 0.031 · Odds ratio (or): 2.98 · 95% CI 1.11 to 8.01
  • Placebo QD vs 12 mg Orforglipron QD · Regression, Logistic · p = 0.087 · Odds ratio (or): 2.38 · 95% CI 0.88 to 6.45
  • Placebo QD vs 36 mg Orforglipron QD · Regression, Logistic · p = 0.296 · Odds ratio (or): 1.72 · 95% CI 0.62 to 4.77
SecondaryPercentage of Participants Who Had Improvements in Dyslipidemia

Percentage of participants achieving dyslipidemia improvement (Low-density lipoprotein cholesterol \<140 milligrams per deciliter (mg/dL), triglycerides \<150 mg/dL, and high-density lipoprotein cholesterol ≥40 mg/dL) was analysed using logistic regression with the following variables: treatment, baseline BMI group, and strata in the model. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). The estimates (odds ratio and corresponding confidence intervals) were derived using observed data.

Time frame:
Baseline to Week 72
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had Improvements in Dyslipidemia
Percentage of ParticipantsPlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants Who Had Improvements in Dyslipidemia60.957.463.665.2
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · Regression, Logistic · p = 0.766 · Odds ratio (or): 0.88 · 95% CI 0.37 to 2.08
  • Placebo QD vs 12 mg Orforglipron QD · Regression, Logistic · p = 0.828 · Odds ratio (or): 1.10 · 95% CI 0.46 to 2.66
  • Placebo QD vs 36 mg Orforglipron QD · Regression, Logistic · p = 0.613 · Odds ratio (or): 1.25 · 95% CI 0.52 to 3.01
SecondaryPercentage of Participants Who Achieve Hemoglobin A1c (HbA1c) Target Value (<6.5% [48 mmol/Mol])

Percentage of participants achieving HbA1c \<6.5% was analysed using logistic regression with the following variables: baseline, treatment, baseline BMI group, and sex in the model, including treatment-by-baseline and treatment-by-sex interaction terms.

Time frame:
Baseline to Week 72
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieve Hemoglobin A1c (HbA1c) Target Value (<6.5% [48 mmol/Mol])
Percentage of ParticipantsPlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants Who Achieve Hemoglobin A1c (HbA1c) Target Value (<6.5% [48 mmol/Mol])031.2545.4578.57
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · Regression, Logistic · p = 0.012 · Risk difference (rd): 27.68 · 95% CI 6.46 to 48.90
  • Placebo QD vs 12 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 51.74 · 95% CI 27.77 to 75.70
  • Placebo QD vs 36 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 81.25 · 95% CI 60.06 to 102.44
SecondaryMean Change From Baseline in Visceral Adipose Tissue (VAT) at Week 72

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Square Centimeter (cm^2)
Mean Change From Baseline in Visceral Adipose Tissue (VAT) at Week 72
Square Centimeter (cm^2)Placebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Mean Change From Baseline in Visceral Adipose Tissue (VAT) at Week 72-7.20 ± 5.220-47.5 ± 5.519-52.3 ± 8.043-49.3 ± 6.526
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -40.3 · 95% CI -55.0 to -25.6
  • Placebo QD vs 12 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -45.1 · 95% CI -64.0 to -26.3
  • Placebo QD vs 36 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -42.1 · 95% CI -57.4 to -26.9
SecondaryMean Change From Baseline in Waist Circumference at Umbilical Level at Week 72

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Centimeter
Mean Change From Baseline in Waist Circumference at Umbilical Level at Week 72
CentimeterPlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Mean Change From Baseline in Waist Circumference at Umbilical Level at Week 72-0.063 ± 0.592-3.67 ± 0.845-5.87 ± 0.851-5.67 ± 0.909
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -3.61 · 95% CI -5.64 to -1.58
  • Placebo QD vs 12 mg Orforglipron QD · ANCOVA · p = <.001 · Mean difference (final values): -5.80 · 95% CI -7.84 to -3.77
  • Placebo QD vs 36 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -5.61 · 95% CI -7.75 to -3.46
SecondaryMean Change From Baseline in Systolic Blood Pressure (SBP) at Week 72

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 72
millimeters of mercury (mmHg)Placebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 72-0.055 ± 1.415-5.08 ± 1.673-3.84 ± 1.636-4.36 ± 1.342
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · ANCOVA · p = 0.019 · Ls mean difference (final values): -5.03 · 95% CI -9.21 to -0.84
  • Placebo QD vs 12 mg Orforglipron QD · ANCOVA · p = 0.059 · Ls mean difference (final values): -3.78 · 95% CI -7.71 to 0.15
  • Placebo QD vs 36 mg Orforglipron QD · ANCOVA · p = 0.021 · Ls mean difference (final values): -4.30 · 95% CI -7.95 to -0.65
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) at Week 72

Values represented as LS means are model-based estimates (MBE) of the unconditional average treatment effect on the log-transformed scale. MBE was calculated using an ANCOVA model for log(Actual Value/Baseline), including log-transformed baseline, treatment, baseline BMI group, and strata (defined by joint levels of sex \[female, male\] and baseline type 2 diabetes status \[yes, no\]) as covariates, with treatment-by-log(baseline) and treatment-by-strata interaction terms included in the model.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) at Week 72
percent changePlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) at Week 720.05 ± 1.711-6.91 ± 2.270-10.20 ± 2.395-10.75 ± 2.352
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · ANCOVA · p = 0.016 · Ls mean difference (final values): -6.96 · 95% CI -12.24 to -1.36
  • Placebo QD vs 12 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -10.25 · 95% CI -15.68 to -4.47
  • Placebo QD vs 36 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -10.79 · 95% CI -16.09 to -5.16
SecondaryPercent Change From Baseline in High Density Lipoprotein (HDL) at Week 72

Values represented as LS means are model-based estimates (MBE) of the unconditional average treatment effect on the log-transformed scale. MBE was calculated using an ANCOVA model for log(Actual Value/Baseline), including log-transformed baseline, treatment, baseline BMI group, and strata (defined by joint levels of sex \[female, male\] and baseline type 2 diabetes status \[yes, no\]) as covariates, with treatment-by-log(baseline) and treatment-by-strata interaction terms included in the model.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High Density Lipoprotein (HDL) at Week 72
percent changePlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percent Change From Baseline in High Density Lipoprotein (HDL) at Week 727.37 ± 2.0795.75 ± 2.3148.62 ± 2.6285.17 ± 2.199
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · ANCOVA · p = 0.591 · Ls mean difference (final values): -1.51 · 95% CI -6.84 to 4.13
  • Placebo QD vs 12 mg Orforglipron QD · ANCOVA · p = 0.705 · Ls mean difference (final values): 1.16 · 95% CI -4.73 to 7.42
  • Placebo QD vs 36 mg Orforglipron QD · ANCOVA · p = 0.466 · Ls mean difference (final values): -2.05 · 95% CI -7.36 to 3.57
SecondaryPercent Change From Baseline in Triglycerides at Week 72

Values represented as LS means are model-based estimates (MBE) of the unconditional average treatment effect on the log-transformed scale. MBE was calculated using an ANCOVA model for log(Actual Value/Baseline), including log-transformed baseline, treatment, baseline BMI group, and strata (defined by joint levels of sex \[female, male\] and baseline type 2 diabetes status \[yes, no\]) as covariates, with treatment-by-log(baseline) and treatment-by-strata interaction terms included in the model.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Triglycerides at Week 72
percent changePlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percent Change From Baseline in Triglycerides at Week 72-9.61 ± 3.015-16.85 ± 4.014-24.85 ± 3.976-15.64 ± 3.772
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · ANCOVA · p = 0.146 · Ls mean difference (final values): -8.02 · 95% CI -17.84 to 2.99
  • Placebo QD vs 12 mg Orforglipron QD · ANCOVA · p = 0.003 · Ls mean difference (final values): -16.86 · 95% CI -26.19 to -6.35
  • Placebo QD vs 36 mg Orforglipron QD · ANCOVA · p = 0.214 · Ls mean difference (final values): -6.67 · 95% CI -16.33 to 4.11
SecondaryMean Change From Baseline in Fasting Glucose at Week 72

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Mean Change From Baseline in Fasting Glucose at Week 72
milligrams per deciliter (mg/dL)Placebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Mean Change From Baseline in Fasting Glucose at Week 72-0.31 ± 1.564-13.98 ± 1.879-15.50 ± 2.163-17.79 ± 1.713
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -13.67 · 95% CI -18.19 to -9.15
  • Placebo QD vs 12 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -15.19 · 95% CI -20.24 to -10.14
  • Placebo QD vs 36 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -17.48 · 95% CI -21.73 to -13.23
SecondaryMean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 72

* Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. * Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an ANCOVA model with the following variables: baseline, treatment, baseline BMI group, and strata in the model, including treatment-by-baseline and treatment-by-strata interaction terms. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Percentage of HbA1c
Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 72
Percentage of HbA1cPlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 720.041 ± 0.0589-0.53 ± 0.0646-0.61 ± 0.0976-0.62 ± 0.0776
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -0.57 · 95% CI -0.75 to -0.40
  • Placebo QD vs 12 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -0.65 · 95% CI -0.88 to -0.43
  • Placebo QD vs 36 mg Orforglipron QD · ANCOVA · p = <.001 · Ls mean difference (final values): -0.66 · 95% CI -0.85 to -0.47
SecondaryMean Change From Baseline in High-sensitivity C-reactive Protein at Week 72

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed model for repeated measures (MMRM) with the following variables: baseline BMI group, baseline-by-time-by-treatment, and strata-by-time-by-treatment interaction terms in the model. Strata were defined by joint levels of sex (female, male) and baseline type 2 diabetes status (yes, no). An unstructured variance-covariance matrix was used.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · milligrams per liter (mg/L)
Mean Change From Baseline in High-sensitivity C-reactive Protein at Week 72
milligrams per liter (mg/L)Placebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Mean Change From Baseline in High-sensitivity C-reactive Protein at Week 72-0.41 ± 0.095-0.34 ± 0.146-0.61 ± 0.070-0.61 ± 0.135
Statistical analysis
  • Placebo QD vs 6 mg Orforglipron QD · Mixed Models Analysis · Ls mean difference (final values): 0.07 · 95% CI -0.27 to 0.41
  • Placebo QD vs 12 mg Orforglipron QD · Mixed Models Analysis · Ls mean difference (final values): -0.19 · 95% CI -0.43 to 0.04
  • Placebo QD vs 36 mg Orforglipron QD · Mixed Models Analysis · Ls mean difference (final values): -0.20 · 95% CI -0.52 to 0.13
SecondaryTime to Onset of Type 2 Diabetes (T2D)

Time to event was defined as the duration from randomization to adjudication committee-confirmed diagnosis of type 2 diabetes mellitus (T2D). Descriptive statistics are presented as Kaplan-Meier estimates of time to onset of T2D (in weeks). Time to onset of T2D was also analyzed using a Cox proportional hazards model, with treatment (pooled orforglipron dose groups) and sex as factors and baseline fasting serum glucose as a covariate. Hazard ratios with corresponding confidence intervals were estimated and reported in statistical analysis. Statistical significance between treatment groups was assessed using a two-sided log-rank test.

Time frame:
Up to Week 72
Reported as:
Median · Weeks
Time to Onset of Type 2 Diabetes (T2D)
WeeksPlacebo QD6/ 12/ 36 mg Orforglipron (Pooled Group)
Time to Onset of Type 2 Diabetes (T2D)2.27 (0.38 to 13.74)0.78 (0.16 to 3.89)
Statistical analysis
  • Placebo QD vs 6/ 12/ 36 mg Orforglipron (Pooled Group) · Log Rank · p = 0.9971 · Hazard ratio (hr): 0.99 · 95% CI 0.04 to 24.73
SecondaryMean Change From Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form For Domain and Component Scores at Week 72

The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Each domain is scored individually and information from these 8 domains is further aggregated into 2 health component summary scores, a Physical Component Summary, and a Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T scores, with mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · T-score
Mean Change From Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form For Domain and Component Scores at Week 72
T-scorePlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Physical Functioning-0.56 ± 0.5960.15 ± 0.5421.44 ± 0.6210.59 ± 0.599
Role-Physical-0.12 ± 0.594-0.58 ± 0.710-0.06 ± 0.584-1.11 ± 0.696
Bodily Pain-1.08 ± 1.075-0.58 ± 1.210-0.56 ± 1.035-1.07 ± 1.269
General Health-0.80 ± 0.6850.02 ± 0.7351.05 ± 0.7450.01 ± 0.659
Vitality-0.65 ± 0.883-0.82 ± 0.943-1.58 ± 0.888-0.080 ± 0.979
Social Functioning-1.19 ± 0.762-1.22 ± 0.900-0.61 ± 0.731-0.48 ± 0.779
Role-Emotional-1.21 ± 1.068-0.22 ± 0.8090.66 ± 0.8510.25 ± 0.816
Mental Health-1.83 ± 1.003-1.65 ± 0.919-0.88 ± 0.793-1.35 ± 1.050
Physical Component Score-0.30 ± 0.642-0.092 ± 0.7650.84 ± 0.6900.011 ± 0.673
Mental Component Score-1.59 ± 1.015-1.08 ± 0.776-0.87 ± 0.819-0.21 ± 0.831
SecondaryMean Change From Baseline in Impact of Weight on Quality-of-Life Lite Clinical Trials Version (IWQOL-Lite-CT) of Physical Function, Physical, and Psychosocial Composite Score at Week 72

The IWQOL-Lite-CT is a 20-item, obesity-specific patient reported outcome instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life: physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. The two domain scores (Physical and Psychosocial) and composite score (Physical function) range from 0 to 100 with higher scores indicating greater functioning. Raw scores are then linearly transformed to a 0 (worst) -100 (best) scale using: 100×(average item score-1)/4. Higher scores indicate better quality of life/function; lower scores indicate greater impairment.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in Impact of Weight on Quality-of-Life Lite Clinical Trials Version (IWQOL-Lite-CT) of Physical Function, Physical, and Psychosocial Composite Score at Week 72
score on a scalePlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Physical Composite Score-2.73 ± 1.9732.32 ± 1.9682.67 ± 1.9612.00 ± 1.728
Physical Function Composite Scores-0.43 ± 1.9033.71 ± 2.0393.08 ± 1.9952.51 ± 1.739
Psychosocial Composite Scores1.74 ± 1.6373.47 ± 1.3165.41 ± 1.5974.02 ± 1.360
SecondaryPharmacokinetics (PK): Mean Plasma Concentration of Orforglipron

Plasma concentrations of orforglipron were measured at predefined pre-dose and post-dose sampling time points.

Time frame:
Pre-dose at Weeks 8, 24, and 48; post-dose at Week 16 (4 to 12 hours) and Week 36 (1 to 4 hours)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Mean Plasma Concentration of Orforglipron
nanograms per milliliter (ng/mL)6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Week 814.5 ± 8.5313.3 ± 8.1615.2 ± 10.5
Week 1654.3 ± 30.5109 ± 51.1153 ± 111
Week 2426.4 ± 15.361.6 ± 43.6155 ± 144
Week 3636.7 ± 21.983.9 ± 98.1173 ± 126
Week 4829.9 ± 15.155.8 ± 37.2146 ± 108

Adverse events

Collected over Baseline up to end of follow-up (up to 74 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo QD0/60 (0%)5/60 (8.3%)47/60 (78.3%)
6 mg Orforglipron QD0/61 (0%)1/61 (1.6%)51/61 (83.6%)
12 mg Orforglipron QD0/57 (0%)3/57 (5.3%)48/57 (84.2%)
36 mg Orforglipron QD1/60 (1.7%)6/60 (10%)51/60 (85%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Chest painGeneral disorders0/600/611/570/60
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/600/611/571/60
Facial paralysisNervous system disorders0/600/611/570/60
Myocardial ischaemiaCardiac disorders0/600/610/571/60
Sudden hearing lossEar and labyrinth disorders0/600/610/571/60
Colitis ischaemicGastrointestinal disorders1/600/610/570/60
AppendicitisInfections and infestations1/600/610/570/60
Atypical mycobacterial infectionInfections and infestations0/600/610/571/60
EpiglottitisInfections and infestations1/600/610/570/60
Post procedural infectionInfections and infestations0/600/610/571/60
Most frequent other events
Showing 10 of 214
Most frequent other events
EventPlacebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
NasopharyngitisInfections and infestations21/6016/6124/5712/60
ConstipationGastrointestinal disorders5/6022/6116/5719/60
NauseaGastrointestinal disorders0/608/619/5720/60
DiarrhoeaGastrointestinal disorders2/609/614/5710/60
VomitingGastrointestinal disorders0/604/615/5710/60
Covid-19Infections and infestations10/604/618/572/60
DyspepsiaGastrointestinal disorders0/602/615/578/60
Abdominal discomfortGastrointestinal disorders2/604/617/571/60
InfluenzaInfections and infestations6/600/614/575/60
Herpes zosterInfections and infestations5/602/610/571/60

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
Mean53.2 ± 11.4453.5 ± 10.3453.5 ± 11.2056.3 ± 11.6554.1 ± 11.17
Sex: Female, Male
Sex: Female, Male(Participants)Placebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
Female2325222494
Male37363536144
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
Hispanic or Latino00000
Not Hispanic or Latino00000
Unknown or Not Reported60615760238
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
American Indian or Alaska Native00000
Asian60615760238
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Placebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
Japan60615760238
Body Weight
Body Weight(Kilogram (Kg))Placebo QD6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
Mean87.78 ± 14.5888.64 ± 13.9588.40 ± 15.1886.69 ± 14.6987.87 ± 14.53
08

Study locations

16 sites
  • Nishiyamadou Keiwa Hospital
    Naka, Ibaraki 311-0133, Japan
  • Tsuchiura Beryl Clinic
    Tsuchiura, Ibaraki 300-0062, Japan
  • Ohishi Internal Medicine Clinic
    Tsuchiura, Ibaraki 300-0835, Japan
  • Shonan Takai Clinic
    Kamakura, Kanagawa 247-0055, Japan
  • Takai Internal Medicine Clinic
    Kamakura-shi, Kanagawa 247-0056, Japan
  • Medical Corporation Yuga Higashirinkan Kaneshiro Diabetes Clinic
    Sagamihara, Kanagawa 252-0302, Japan
  • Shiraiwa Medical Clinic
    Kashihara, Osaka 582-0005, Japan
  • Medical Corporation Heishinkai OCROM Clinic
    Suita-shi, Osaka 565-0853, Japan
  • Sugiura Clinic
    Kawaguchi, Saitama 332-0012, Japan
  • Yotsuya Medical Cube
    Chiyoda City, Tokyo 102-0084, Japan
  • Nihonbashi Sakura Clinic
    Chuo-ku, Tokyo 103-0025, Japan
  • Tokyo-Eki Center-building Clinic
    Chuo-ku, Tokyo 103-0027, Japan
  • Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • Heishinkai Medical Group ToCROM Clinic
    Shinjuku-ku, Tokyo 160-0008, Japan
  • Hiroshima Station Clinic
    Hiroshima, 732-0053, Japan
  • Osaka Nishiumeda Clinic
    Osaka, 530-0001, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jun 2025, 22 months.

Results were first posted in Jul 2026, 1 year 1 month after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 22 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jul 5, 2023
StartActual
Jul 31, 2023
Primary completionActual
Jun 19, 2025
CompletionActual
Jun 19, 2025
Results first posted
Jul 20, 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05931380
Responsible party
Sponsor
First posted
Jul 5, 2023
Start date
Jul 31, 2023
Primary completion
Jun 19, 2025
Completion
Jun 19, 2025
Results posted
Jul 20, 2026
Last update
Jul 20, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion